Strategic positioning for clinical trials in 2021
MyMD will commence a Phase 2 clinical trial of MYMD-1 in COVID19 associated depression in 2021. In addition, we expect to advance MYMD-1 into a phase 2 clinical trial for treatment of diabetes, rheumatoid arthritis, Sarcopenia (aging) and multiple sclerosis. We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders.
